Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to -$974000.0.

  • Celldex Therapeutics' Change in Receivables rose 1433.6% to -$974000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$762000.0, marking a year-over-year decrease of 22700.0%. This contributed to the annual value of -$1.9 million for FY2024, which is 18452.43% down from last year.
  • Celldex Therapeutics' Change in Receivables amounted to -$974000.0 in Q2 2025, which was up 1433.6% from $364000.0 recorded in Q1 2025.
  • In the past 5 years, Celldex Therapeutics' Change in Receivables ranged from a high of $2.4 million in Q4 2023 and a low of -$1.3 million during Q2 2021
  • Its 5-year average for Change in Receivables is -$92000.0, with a median of $500.0 in 2021.
  • The largest annual percentage gain for Celldex Therapeutics' Change in Receivables in the last 5 years was 140379.75% (2023), contrasted with its biggest fall of 71917.81% (2023).
  • Over the past 5 years, Celldex Therapeutics' Change in Receivables (Quarter) stood at -$25000.0 in 2021, then soared by 732.0% to $158000.0 in 2022, then soared by 1403.8% to $2.4 million in 2023, then tumbled by 106.4% to -$152000.0 in 2024, then tumbled by 540.79% to -$974000.0 in 2025.
  • Its Change in Receivables stands at -$974000.0 for Q2 2025, versus $364000.0 for Q1 2025 and -$152000.0 for Q4 2024.